Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
Patent 5708036 Issued on January 13, 1998. Estimated Expiration Date: 
January 29, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 29, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesSingle layer transdermal drug administration system Single layer transdermal drug administration system Method for treating asthma using optically pure (R)-albuterol Patent #: 5362755 InventorApplicationNo. 592988 filed on 01/29/1996US Classes:514/653, Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.)514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/935UTERINE MOTILITYExaminersPrimary: Cintins, Marianne M.Assistant: Moezie, M. Attorney, Agent or FirmInternational ClassA61K 031/135AbstractThe optically pure R-isomer of the adrenergic beta-2 agonist albuterol, substantially free of its corresponding S-isomer, has been found to potently inhibit premature uterine contractions in female subjects, suffering from said condition, while avoiding side effects associated with the corresponding S-isomer. A new method is disclosed utilizing the optically pure R(-)-isomer of albuterol for treating premature uterine contractions while minimizing the side effects associated with administration of racemic albuterol. | |
